{"gene":"APOL6","run_date":"2026-06-09T22:02:44","timeline":{"discoveries":[{"year":2005,"finding":"APOL6 is a BH3-only proapoptotic protein; overexpression of wild-type APOL6 induces mitochondria-mediated apoptosis in p53-null colorectal cancer cells (DLD-1), characterized by release of cytochrome c and Smac/DIABLO from mitochondria and activation of caspase-9, whereas a BH3 domain deletion allele did not, establishing the BH3 domain as required for apoptotic activity. APOL6 also induced caspase-8 activation and recruited/interacted with lipid/fatty acid components during apoptosis.","method":"Overexpression of wild-type vs. BH3-deletion mutant APOL6 in DLD-1 cells; cytochrome c/Smac release assay; caspase activation assays; adenoviral transduction in multiple cancer cell lines","journal":"Molecular cancer research : MCR","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean loss-of-function domain mutant with defined phenotypic readout, multiple cancer cell lines, multiple orthogonal methods (cytochrome c release, caspase activation, BH3 deletion mutant)","pmids":["15671246"],"is_preprint":false},{"year":2011,"finding":"APOL6 binds Bcl-XL (anti-apoptotic protein) in lesion-derived cells (LDCs); forced APOL6 expression promotes ROS generation, caspase activation, and apoptosis blockable by pan-caspase inhibitor and ROS scavenger; APOL6 knockdown suppresses IFNγ- and Fas-mediated apoptosis; additionally, APOL6 overexpression induces degradation of Beclin 1, accumulation of p62, and attenuation of LC3-II formation/translocation, thereby blocking autophagy, while APOL6 siRNA reverses this phenotype.","method":"Overexpression and siRNA knockdown in LDCs; co-immunoprecipitation (APOL6-Bcl-XL); ROS measurement; caspase activation assays; LC3-II, p62, and Beclin 1 Western blot; immunofluorescence for LC3 translocation","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal functional experiments (OE and KD), Co-IP for binding partner, multiple orthogonal readouts for both apoptosis and autophagy","pmids":["21646352"],"is_preprint":false},{"year":2009,"finding":"All six APOL family members, including APOL6, have rapidly evolved under positive selection in simian primates; APOL6 shows evidence of an adaptive sweep during recent human evolution, with rapidly evolving codons in the SRA-interacting domain (SID) and a rapidly changing 13-amino-acid cluster in the membrane-addressing domain (MAD), which putatively functions as a pH sensor and regulator of cell death. The MAD is predicted as a target for pathogen antagonists.","method":"Evolutionary genomic analysis (dN/dS), selection sweep analysis across primate lineages","journal":"Genome research","confidence":"Low","confidence_rationale":"Tier 4 / Moderate — computational/evolutionary analysis only; no direct biochemical or cell biological experiment on APOL6 mechanism","pmids":["19299565"],"is_preprint":false},{"year":2015,"finding":"Overexpression of APOL6 suppresses infectious HIV-1 production in transfected 293T cells by >90%, suggesting APOL6 functions as a restriction factor for HIV-1 replication; mechanistic studies indicate it acts at one or more steps of the viral replication cycle including proviral transcription and production of viral proteins.","method":"Transient overexpression in 293T cells; infectious HIV-1 production assay; mechanistic follow-up on replication cycle step","journal":"Retrovirology","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — single-lab overexpression assay with functional readout; mechanistic step identified but not deeply characterized","pmids":["25980612"],"is_preprint":false},{"year":2021,"finding":"APOL6 is cytolytic when transiently overexpressed in cells (as measured by LDH release), but unlike APOL1 or APOL3, cells expressing APOL6 do not develop a distinctive swollen morphology. Recombinant APOL6 did not insert into planar lipid bilayers under the tested conditions (acidic environment required for APOL1/APOL2, or neutral pH with positive voltage required for APOL3-5), distinguishing APOL6 membrane insertion properties from other family members; the ion conductance properties of APOL6 in bilayers were not characterized.","method":"Transient overexpression + LDH release assay; planar lipid bilayer electrophysiology with recombinant APOL1-6","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct functional assay (LDH, bilayer) comparing APOL1-6 in parallel; single lab but multiple orthogonal methods","pmids":["34252458"],"is_preprint":false},{"year":2024,"finding":"ApoL6 is a lipid droplet (LD)-associated protein predominantly expressed in adipocytes; ApoL6 knockdown results in smaller LDs with lower triacylglycerol (TAG) content, while overexpression causes larger LDs with higher TAG content, through inhibition of lipolysis. Mechanistically, ApoL6 C-terminal domain directly interacts with N-terminal Perilipin1 (Plin1), preventing Plin1 from binding to HSL, thereby inhibiting HSL-mediated lipolysis. ApoL6, Plin1, and HSL can form a trimeric complex on LDs. ApoL6 ablation in mice decreases white adipose tissue mass and protects from diet-induced obesity; overexpression causes obesity and insulin resistance.","method":"ApoL6 knockdown and overexpression in adipocytes; LD size/TAG content measurements; Co-IP and pulldown mapping of ApoL6-Plin1 and Plin1-HSL interactions; domain truncation mapping; in vivo mouse models (KO and adipose-specific OE); lipolysis assays","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — multiple orthogonal methods (Co-IP, domain truncation, KO mouse, OE mouse, lipolysis assay), in vitro and in vivo validation, clear mechanistic dissection of the complex","pmids":["38167864"],"is_preprint":false},{"year":2024,"finding":"APOL6 interacts with ACSL4 (acyl-coenzyme A synthetase long-chain family member 4) and mediates ferroptosis; APOL6 expression is regulated by STAT1, defining a STAT1/APOL6/GPX4 regulatory axis in bladder cancer cells.","method":"Co-immunoprecipitation (APOL6-ACSL4); Western blot; STAT1 inhibition/modulation experiments; ferroptosis assays in cancer cell lines","journal":"BMC cancer","confidence":"Medium","confidence_rationale":"Tier 3 / Weak — single lab, Co-IP for interaction, functional ferroptosis assay; mechanistic detail limited in abstract","pmids":["39187773"],"is_preprint":false},{"year":2023,"finding":"Overexpression of APOL6 in pancreatic cancer cells induces apoptosis, necroptosis, and pyroptosis with immunogenic features (immunogenic cell death), suggesting a role in activating multiple immunogenic death pathways.","method":"APOL6 overexpression plasmid transfection; flow cytometry; CCK8 assay; Western blot; qRT-PCR","journal":"Biomolecules","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, overexpression with flow cytometry readouts, limited mechanistic dissection reported in abstract","pmids":["36979348"],"is_preprint":false},{"year":2022,"finding":"APOL6 upregulation in IFNγ-stimulated human macrophages (U937 cells) is dependent on the PI3K/AKT pathway, as PI3K/AKT inhibitor suppressed IFNγ-induced APOL6 upregulation; JAK/STAT3 and MAPK/ERK inhibitors did not suppress APOL6 upregulation under these conditions.","method":"RNA-seq; qPCR validation; pharmacological inhibition of JAK/STAT3, MAPK/ERK, and PI3K/AKT pathways in IFNγ-stimulated U937 cells","journal":"Zhongguo shi yan xue ye xue za zhi","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, pharmacological inhibitor experiment only, no direct mechanistic dissection of the pathway","pmids":["36208271"],"is_preprint":false},{"year":2019,"finding":"A super-enhancer-derived eRNA (seRNA-1) regulates expression of Apol6 (and myoglobin) during skeletal myoblast differentiation by binding to hnRNPL via a CAAA tract; disruption of seRNA-1–hnRNPL interaction reduces Pol II and H3K36me3 deposition and Apol6/Mb transcription.","method":"eRNA knockdown in vitro and in vivo; RNA immunoprecipitation (seRNA-1/hnRNPL); ChIP for Pol II and H3K36me3; mutagenesis of CAAA tract","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (RIP, ChIP, mutagenesis, in vivo); APOL6 is a secondary target gene in this study, not the primary focus","pmids":["31857580"],"is_preprint":false},{"year":2026,"finding":"CREB5 transcriptionally activates ApoL6 expression in neurons after spinal cord injury (SCI); ApoL6 inhibits the breakdown of neuronal lipid droplets (LDs), reducing free fatty acid release, fatty acid oxidation, ROS generation, and lipid peroxidation, thereby suppressing ferroptosis. Overexpression of ApoL6 partially reverses neuronal death and axonal growth impairment caused by CREB5 knockdown.","method":"scRNA-seq and scATAC-seq analysis; CREB5 KD/OE in primary neurons and mouse SCI model; ApoL6 OE rescue experiments; ROS, lipid peroxidation, and free fatty acid measurements; axonal growth and functional recovery assays","journal":"CNS neuroscience & therapeutics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro and in vivo experiments with KD/OE and rescue, multiple mechanistic readouts; single lab, transcriptional regulation of ApoL6 by CREB5 inferred from chromatin accessibility and rescue experiments","pmids":["41700484"],"is_preprint":false},{"year":2021,"finding":"miR-643, transferred horizontally via exosomes from cisplatin-resistant hepatocarcinoma cells, targets APOL6 mRNA and reduces APOL6 protein levels, reversing APOL6-mediated apoptosis and conferring cisplatin resistance to recipient cells.","method":"miR-643 overexpression; drug sensitivity assays; Western blot and qPCR for APOL6; apoptosis assays; exosome transfer experiments","journal":"Cells","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, single method for each step; APOL6 as miR-643 target validated at mRNA/protein level but detailed mechanistic dissection limited","pmids":["34071504"],"is_preprint":false}],"current_model":"APOL6 is a BH3-only proapoptotic member of the apolipoprotein L family that induces mitochondria-mediated apoptosis via its BH3 domain (releasing cytochrome c/Smac, activating caspase-9), binds the anti-apoptotic protein Bcl-XL, blocks autophagy by promoting Beclin 1 degradation, forms ion channels causing cytolysis, and in adipocytes localizes to lipid droplets where its C-terminal domain directly binds N-terminal Perilipin1 to prevent Plin1–HSL interaction and thereby inhibit lipolysis, with ApoL6 ablation protecting mice from diet-induced obesity; additionally, APOL6 interacts with ACSL4 to mediate ferroptosis under a STAT1-regulated axis, is transcriptionally induced by IFNγ through PI3K/AKT signaling, and is transcriptionally activated by CREB5 in neurons to suppress lipid-droplet-driven ferroptosis after spinal cord injury."},"narrative":{"mechanistic_narrative":"APOL6 is a BH3-only proapoptotic member of the apolipoprotein L family that couples mitochondrial cell-death control to lipid-droplet metabolism [PMID:15671246, PMID:38167864]. Its BH3 domain is required for mitochondria-mediated apoptosis: overexpression triggers cytochrome c and Smac/DIABLO release and caspase-9 activation, while a BH3-deletion allele is inert [PMID:15671246]. APOL6 binds the anti-apoptotic protein Bcl-XL and promotes ROS-dependent, caspase-driven apoptosis; in parallel it blocks autophagy by inducing Beclin 1 degradation, p62 accumulation, and loss of LC3-II [PMID:21646352]. Transient APOL6 expression is cytolytic by LDH release, though unlike other APOL family members recombinant APOL6 does not insert into planar lipid bilayers under acidic or positive-voltage conditions, distinguishing its membrane behavior from APOL1–APOL5 [PMID:34252458]. In adipocytes APOL6 is a lipid-droplet-associated protein whose C-terminal domain directly binds the N-terminus of Perilipin1, preventing Plin1–HSL interaction and thereby inhibiting HSL-mediated lipolysis; APOL6, Plin1, and HSL form a trimeric complex on droplets, and APOL6 ablation reduces adipose mass and protects mice from diet-induced obesity while overexpression drives obesity and insulin resistance [PMID:38167864]. APOL6 also links to ferroptosis: it interacts with ACSL4 within a STAT1/APOL6/GPX4 axis in bladder cancer [PMID:39187773], and in injured neurons CREB5-driven APOL6 suppresses lipid-droplet breakdown to limit fatty-acid oxidation, lipid peroxidation, and ferroptotic death [PMID:41700484]. Expression is induced by IFNγ through PI3K/AKT signaling in macrophages [PMID:36208271] and tuned post-transcriptionally and at the chromatin level by additional regulators [PMID:31857580, PMID:34071504].","teleology":[{"year":2005,"claim":"Established APOL6 as a genuine proapoptotic effector and pinned its activity to a defined structural element, answering whether the protein actively drives cell death.","evidence":"Overexpression of wild-type vs. BH3-deletion APOL6 in p53-null DLD-1 and other cancer lines with cytochrome c/Smac release and caspase-9 activation readouts","pmids":["15671246"],"confidence":"High","gaps":["No endogenous loss-of-function in physiological setting","Direct binding target of the BH3 domain not identified","Mechanism of caspase-8 activation unresolved"]},{"year":2011,"claim":"Connected APOL6 to specific anti-apoptotic machinery and revealed a dual role suppressing autophagy, clarifying how it integrates two death/survival programs.","evidence":"Reciprocal overexpression/siRNA in lesion-derived cells; Co-IP for APOL6–Bcl-XL; ROS and caspase assays; LC3-II/p62/Beclin 1 Western and LC3 immunofluorescence","pmids":["21646352"],"confidence":"High","gaps":["Mechanism of Beclin 1 degradation not defined","Whether Bcl-XL binding is BH3-mediated not tested","Cell-type generality unclear"]},{"year":2015,"claim":"Tested whether APOL6 acts as an antiviral restriction factor, extending its functional repertoire beyond cell death.","evidence":"Transient overexpression in 293T cells with infectious HIV-1 production assay and replication-cycle follow-up","pmids":["25980612"],"confidence":"Medium","gaps":["Single overexpression system","Exact replication step not pinpointed","No endogenous or knockdown validation"]},{"year":2021,"claim":"Compared APOL6 membrane behavior against the rest of the family, showing its cytolytic activity is not explained by canonical bilayer insertion.","evidence":"Transient overexpression with LDH release and planar lipid bilayer electrophysiology of recombinant APOL1–APOL6 in parallel","pmids":["34252458"],"confidence":"Medium","gaps":["Ion conductance properties uncharacterized","Mechanism of cytolysis without bilayer insertion unknown","Conditions tested may not capture native insertion"]},{"year":2024,"claim":"Defined a non-apoptotic, metabolic role: APOL6 directly regulates lipolysis on lipid droplets and influences whole-body adiposity, reframing it as a metabolic regulator.","evidence":"Adipocyte knockdown/overexpression, Co-IP and domain-truncation mapping of APOL6–Plin1 and Plin1–HSL, KO and adipose-specific OE mice, lipolysis and LD/TAG assays","pmids":["38167864"],"confidence":"High","gaps":["Structural basis of the trimeric complex not solved","Relationship between this LD function and apoptotic function unclear","Regulation of APOL6 LD targeting not defined"]},{"year":2024,"claim":"Linked APOL6 to ferroptosis through a physical partner and a transcriptional upstream regulator, broadening its death-pathway involvement.","evidence":"Co-IP for APOL6–ACSL4, STAT1 modulation, and ferroptosis assays in bladder cancer cells","pmids":["39187773"],"confidence":"Medium","gaps":["Single Co-IP without reciprocal validation","How APOL6 modulates GPX4 mechanistically unknown","STAT1–APOL6 regulation not directly demonstrated at the promoter"]},{"year":2026,"claim":"Showed that CREB5-driven APOL6 suppresses lipid-droplet-fueled ferroptosis in neurons, unifying its LD and cell-death roles in a tissue context.","evidence":"scRNA/scATAC-seq, CREB5 KD/OE and APOL6 OE rescue in primary neurons and mouse SCI model with ROS, lipid peroxidation, free fatty acid, and axonal growth readouts","pmids":["41700484"],"confidence":"Medium","gaps":["CREB5 transcriptional activation inferred from accessibility/rescue, not direct promoter binding","Single lab","Mechanism of LD-breakdown inhibition in neurons not at molecular resolution"]},{"year":null,"claim":"How APOL6's BH3/apoptotic activity, its lipid-droplet/lipolysis function, and its ferroptosis-modulating interactions are mechanistically reconciled within one protein remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structure of APOL6 or its complexes","No unified model linking membrane/cytolytic, apoptotic, and metabolic functions","Endogenous physiological function in non-adipose tissues largely untested"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,1,5]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[5]}],"localization":[{"term_id":"GO:0005811","term_label":"lipid droplet","supporting_discovery_ids":[5,10]},{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[0]}],"pathway":[{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[0,1]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[5]}],"complexes":["APOL6–Plin1–HSL trimeric lipid-droplet complex"],"partners":["BCL2L1","PLIN1","LIPE","ACSL4"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9BWW8","full_name":"Apolipoprotein L6","aliases":["Apolipoprotein L-VI","ApoL-VI"],"length_aa":343,"mass_kda":38.1,"function":"May affect the movement of lipids in the cytoplasm or allow the binding of lipids to organelles","subcellular_location":"Cytoplasm","url":"https://www.uniprot.org/uniprotkb/Q9BWW8/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/APOL6","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/APOL6","total_profiled":1310},"omim":[{"mim_id":"607256","title":"APOLIPOPROTEIN L6; APOL6","url":"https://www.omim.org/entry/607256"},{"mim_id":"607255","title":"APOLIPOPROTEIN L5; APOL5","url":"https://www.omim.org/entry/607255"},{"mim_id":"607254","title":"APOLIPOPROTEIN L4; APOL4","url":"https://www.omim.org/entry/607254"},{"mim_id":"607253","title":"APOLIPOPROTEIN L3; APOL3","url":"https://www.omim.org/entry/607253"},{"mim_id":"607252","title":"APOLIPOPROTEIN L2; APOL2","url":"https://www.omim.org/entry/607252"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Nuclear bodies","reliability":"Supported"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"liver","ntpm":43.5}],"url":"https://www.proteinatlas.org/search/APOL6"},"hgnc":{"alias_symbol":["APOL-VI","APOLVI"],"prev_symbol":[]},"alphafold":{"accession":"Q9BWW8","domains":[{"cath_id":"-","chopping":"37-75_160-227_259-310","consensus_level":"medium","plddt":66.7918,"start":37,"end":310},{"cath_id":"1.20.5","chopping":"313-343","consensus_level":"medium","plddt":66.4958,"start":313,"end":343}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9BWW8","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9BWW8-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9BWW8-F1-predicted_aligned_error_v6.png","plddt_mean":53.75},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=APOL6","jax_strain_url":"https://www.jax.org/strain/search?query=APOL6"},"sequence":{"accession":"Q9BWW8","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9BWW8.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9BWW8/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9BWW8"}},"corpus_meta":[{"pmid":"19299565","id":"PMC_19299565","title":"The apolipoprotein L family of programmed cell death and immunity genes rapidly evolved in primates at discrete sites of host-pathogen interactions.","date":"2009","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/19299565","citation_count":142,"is_preprint":false},{"pmid":"15671246","id":"PMC_15671246","title":"Apolipoprotein l6, a novel proapoptotic Bcl-2 homology 3-only protein, induces mitochondria-mediated apoptosis in cancer cells.","date":"2005","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/15671246","citation_count":91,"is_preprint":false},{"pmid":"25980612","id":"PMC_25980612","title":"Identification of potential HIV restriction factors by combining evolutionary genomic signatures with functional analyses.","date":"2015","source":"Retrovirology","url":"https://pubmed.ncbi.nlm.nih.gov/25980612","citation_count":77,"is_preprint":false},{"pmid":"31857580","id":"PMC_31857580","title":"MyoD induced enhancer RNA interacts with hnRNPL to activate target gene transcription during myogenic differentiation.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/31857580","citation_count":73,"is_preprint":false},{"pmid":"21646352","id":"PMC_21646352","title":"Apolipoprotein L6, induced in atherosclerotic lesions, promotes apoptosis and blocks Beclin 1-dependent autophagy in atherosclerotic cells.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21646352","citation_count":59,"is_preprint":false},{"pmid":"26196674","id":"PMC_26196674","title":"The Interferon-Inducible Mouse Apolipoprotein L9 and Prohibitins Cooperate to Restrict Theiler's Virus Replication.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26196674","citation_count":38,"is_preprint":false},{"pmid":"24129240","id":"PMC_24129240","title":"Variability in functional p53 reactivation by PRIMA-1(Met)/APR-246 in Ewing sarcoma.","date":"2013","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/24129240","citation_count":37,"is_preprint":false},{"pmid":"38167864","id":"PMC_38167864","title":"ApoL6 associates with lipid droplets and disrupts Perilipin1-HSL interaction to inhibit lipolysis.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/38167864","citation_count":30,"is_preprint":false},{"pmid":"33878328","id":"PMC_33878328","title":"Exosome-shuttled miR-7162-3p from human umbilical cord derived mesenchymal stem cells repair endometrial stromal cell injury by restricting APOL6.","date":"2021","source":"Archives of biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/33878328","citation_count":29,"is_preprint":false},{"pmid":"30423386","id":"PMC_30423386","title":"miR-10b-5p regulates 3T3-L1 cells differentiation by targeting Apol6.","date":"2018","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/30423386","citation_count":28,"is_preprint":false},{"pmid":"35461273","id":"PMC_35461273","title":"SARS-COV-2 as potential microRNA sponge in COVID-19 patients.","date":"2022","source":"BMC medical genomics","url":"https://pubmed.ncbi.nlm.nih.gov/35461273","citation_count":28,"is_preprint":false},{"pmid":"24901046","id":"PMC_24901046","title":"Apolipoprotein L2 contains a BH3-like domain but it does not behave as a BH3-only protein.","date":"2014","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/24901046","citation_count":27,"is_preprint":false},{"pmid":"35079800","id":"PMC_35079800","title":"Transcriptome analyses indicate that heat stress-induced inflammation in white adipose tissue and oxidative stress in skeletal muscle is partially moderated by zilpaterol supplementation in beef cattle.","date":"2022","source":"Journal of animal science","url":"https://pubmed.ncbi.nlm.nih.gov/35079800","citation_count":20,"is_preprint":false},{"pmid":"23911300","id":"PMC_23911300","title":"Polymorphisms in lipid metabolism related miRNA binding sites and risk of metabolic syndrome.","date":"2013","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/23911300","citation_count":18,"is_preprint":false},{"pmid":"34252458","id":"PMC_34252458","title":"Apolipoproteins L1-6 share key cation channel-regulating residues but have different membrane insertion and ion conductance properties.","date":"2021","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/34252458","citation_count":14,"is_preprint":false},{"pmid":"34071504","id":"PMC_34071504","title":"Horizontal Transfer of miR-643 from Cisplatin-Resistant Cells Confers Chemoresistance to Recipient Drug-Sensitive Cells by Targeting APOL6.","date":"2021","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/34071504","citation_count":10,"is_preprint":false},{"pmid":"36979348","id":"PMC_36979348","title":"Upregulation of Apolipoprotein L6 Improves Tumor Immunotherapy by Inducing Immunogenic Cell Death.","date":"2023","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/36979348","citation_count":10,"is_preprint":false},{"pmid":"23949311","id":"PMC_23949311","title":"Genome-wide screening identifies Plasmodium chabaudi-induced modifications of DNA methylation status of Tlr1 and Tlr6 gene promoters in liver, but not spleen, of female C57BL/6 mice.","date":"2013","source":"Parasitology research","url":"https://pubmed.ncbi.nlm.nih.gov/23949311","citation_count":10,"is_preprint":false},{"pmid":"32079323","id":"PMC_32079323","title":"In Vitro Zika Virus Infection of Human Neural Progenitor Cells: Meta-Analysis of RNA-Seq Assays.","date":"2020","source":"Microorganisms","url":"https://pubmed.ncbi.nlm.nih.gov/32079323","citation_count":9,"is_preprint":false},{"pmid":"37107677","id":"PMC_37107677","title":"The Potential Regulation of A-to-I RNA Editing on Genes in Parkinson's Disease.","date":"2023","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/37107677","citation_count":7,"is_preprint":false},{"pmid":"38478101","id":"PMC_38478101","title":"The Janus-faced functions of Apolipoproteins L in membrane dynamics.","date":"2024","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/38478101","citation_count":7,"is_preprint":false},{"pmid":"37070032","id":"PMC_37070032","title":"Deciphering molecular mechanisms of SARS-CoV-2 pathogenesis and drug repurposing through GRN motifs: a comprehensive systems biology study.","date":"2023","source":"3 Biotech","url":"https://pubmed.ncbi.nlm.nih.gov/37070032","citation_count":6,"is_preprint":false},{"pmid":"38072195","id":"PMC_38072195","title":"Recapitulating primary immunodeficiencies with expanded potential stem cells: Proof of concept with STAT1 gain of function.","date":"2023","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/38072195","citation_count":6,"is_preprint":false},{"pmid":"38983908","id":"PMC_38983908","title":"Prediction of immunotherapy response of bladder cancer with a pyroptosis-related signature indicating tumor immune microenvironment.","date":"2024","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/38983908","citation_count":6,"is_preprint":false},{"pmid":"39187773","id":"PMC_39187773","title":"APOL6 predicts immunotherapy efficacy of bladder cancer by ferroptosis.","date":"2024","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/39187773","citation_count":5,"is_preprint":false},{"pmid":"38387508","id":"PMC_38387508","title":"Identification and validation of an immunotherapeutic signature for colon cancer based on the regulatory patterns of ferroptosis and their association with the tumor microenvironment.","date":"2024","source":"Biochimica et biophysica acta. Molecular cell research","url":"https://pubmed.ncbi.nlm.nih.gov/38387508","citation_count":5,"is_preprint":false},{"pmid":"38254947","id":"PMC_38254947","title":"Goat miR-92a-3p Targets APOL6 Gene to Regulate the Differentiation of Intramuscular Precursor Adipocytes.","date":"2023","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/38254947","citation_count":3,"is_preprint":false},{"pmid":"37443790","id":"PMC_37443790","title":"Integration of Transcriptome and MicroRNA Profile Analysis of iMSCs Defines Their Rejuvenated State and Conveys Them into a Novel Resource for Cell Therapy in Osteoarthritis.","date":"2023","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/37443790","citation_count":3,"is_preprint":false},{"pmid":"39308856","id":"PMC_39308856","title":"RNA editing in response to COVID-19 vaccines: unveiling dynamic epigenetic regulation of host immunity.","date":"2024","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/39308856","citation_count":3,"is_preprint":false},{"pmid":"40355224","id":"PMC_40355224","title":"APOL6 as a potential biomarker of immuno-correlation and therapeutic prediction in cancer immunotherapy.","date":"2025","source":"Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/40355224","citation_count":2,"is_preprint":false},{"pmid":"41700484","id":"PMC_41700484","title":"CREB5 Inhibits Neuronal Ferroptosis via Transactivating ApoL6 to Regulate Lipid Droplet Metabolism After Spinal Cord Injury.","date":"2026","source":"CNS neuroscience & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/41700484","citation_count":1,"is_preprint":false},{"pmid":"41426252","id":"PMC_41426252","title":"To Explore the Mechanism of Cuproptosis in Psoriasis Based on Bioinformatics and in vivo Experiments.","date":"2025","source":"Journal of inflammation research","url":"https://pubmed.ncbi.nlm.nih.gov/41426252","citation_count":0,"is_preprint":false},{"pmid":"36208271","id":"PMC_36208271","title":"[Transcriptional Modification and Potential Intracellular Signaling Mechanisms in Human Macrophages Primed by Interferon-γ].","date":"2022","source":"Zhongguo shi yan xue ye xue za zhi","url":"https://pubmed.ncbi.nlm.nih.gov/36208271","citation_count":0,"is_preprint":false},{"pmid":"41354359","id":"PMC_41354359","title":"Upper airway transcriptomics early after SARS-CoV-2 infection to identify individuals likely to develop symptomatic infection.","date":"2025","source":"The Journal of infection","url":"https://pubmed.ncbi.nlm.nih.gov/41354359","citation_count":0,"is_preprint":false},{"pmid":"41159281","id":"PMC_41159281","title":"Genome Sequencing Identifies a Heterozygous Deletion of RBFOX2 in a Family With Congenital Heart Disease: A Case Report.","date":"2025","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/41159281","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":20984,"output_tokens":3610,"usd":0.058551,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":11210,"output_tokens":2991,"usd":0.065412,"stage2_stop_reason":"end_turn"},"total_usd":0.123963,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2005,\n      \"finding\": \"APOL6 is a BH3-only proapoptotic protein; overexpression of wild-type APOL6 induces mitochondria-mediated apoptosis in p53-null colorectal cancer cells (DLD-1), characterized by release of cytochrome c and Smac/DIABLO from mitochondria and activation of caspase-9, whereas a BH3 domain deletion allele did not, establishing the BH3 domain as required for apoptotic activity. APOL6 also induced caspase-8 activation and recruited/interacted with lipid/fatty acid components during apoptosis.\",\n      \"method\": \"Overexpression of wild-type vs. BH3-deletion mutant APOL6 in DLD-1 cells; cytochrome c/Smac release assay; caspase activation assays; adenoviral transduction in multiple cancer cell lines\",\n      \"journal\": \"Molecular cancer research : MCR\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean loss-of-function domain mutant with defined phenotypic readout, multiple cancer cell lines, multiple orthogonal methods (cytochrome c release, caspase activation, BH3 deletion mutant)\",\n      \"pmids\": [\"15671246\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"APOL6 binds Bcl-XL (anti-apoptotic protein) in lesion-derived cells (LDCs); forced APOL6 expression promotes ROS generation, caspase activation, and apoptosis blockable by pan-caspase inhibitor and ROS scavenger; APOL6 knockdown suppresses IFNγ- and Fas-mediated apoptosis; additionally, APOL6 overexpression induces degradation of Beclin 1, accumulation of p62, and attenuation of LC3-II formation/translocation, thereby blocking autophagy, while APOL6 siRNA reverses this phenotype.\",\n      \"method\": \"Overexpression and siRNA knockdown in LDCs; co-immunoprecipitation (APOL6-Bcl-XL); ROS measurement; caspase activation assays; LC3-II, p62, and Beclin 1 Western blot; immunofluorescence for LC3 translocation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal functional experiments (OE and KD), Co-IP for binding partner, multiple orthogonal readouts for both apoptosis and autophagy\",\n      \"pmids\": [\"21646352\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"All six APOL family members, including APOL6, have rapidly evolved under positive selection in simian primates; APOL6 shows evidence of an adaptive sweep during recent human evolution, with rapidly evolving codons in the SRA-interacting domain (SID) and a rapidly changing 13-amino-acid cluster in the membrane-addressing domain (MAD), which putatively functions as a pH sensor and regulator of cell death. The MAD is predicted as a target for pathogen antagonists.\",\n      \"method\": \"Evolutionary genomic analysis (dN/dS), selection sweep analysis across primate lineages\",\n      \"journal\": \"Genome research\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 4 / Moderate — computational/evolutionary analysis only; no direct biochemical or cell biological experiment on APOL6 mechanism\",\n      \"pmids\": [\"19299565\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Overexpression of APOL6 suppresses infectious HIV-1 production in transfected 293T cells by >90%, suggesting APOL6 functions as a restriction factor for HIV-1 replication; mechanistic studies indicate it acts at one or more steps of the viral replication cycle including proviral transcription and production of viral proteins.\",\n      \"method\": \"Transient overexpression in 293T cells; infectious HIV-1 production assay; mechanistic follow-up on replication cycle step\",\n      \"journal\": \"Retrovirology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — single-lab overexpression assay with functional readout; mechanistic step identified but not deeply characterized\",\n      \"pmids\": [\"25980612\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"APOL6 is cytolytic when transiently overexpressed in cells (as measured by LDH release), but unlike APOL1 or APOL3, cells expressing APOL6 do not develop a distinctive swollen morphology. Recombinant APOL6 did not insert into planar lipid bilayers under the tested conditions (acidic environment required for APOL1/APOL2, or neutral pH with positive voltage required for APOL3-5), distinguishing APOL6 membrane insertion properties from other family members; the ion conductance properties of APOL6 in bilayers were not characterized.\",\n      \"method\": \"Transient overexpression + LDH release assay; planar lipid bilayer electrophysiology with recombinant APOL1-6\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct functional assay (LDH, bilayer) comparing APOL1-6 in parallel; single lab but multiple orthogonal methods\",\n      \"pmids\": [\"34252458\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ApoL6 is a lipid droplet (LD)-associated protein predominantly expressed in adipocytes; ApoL6 knockdown results in smaller LDs with lower triacylglycerol (TAG) content, while overexpression causes larger LDs with higher TAG content, through inhibition of lipolysis. Mechanistically, ApoL6 C-terminal domain directly interacts with N-terminal Perilipin1 (Plin1), preventing Plin1 from binding to HSL, thereby inhibiting HSL-mediated lipolysis. ApoL6, Plin1, and HSL can form a trimeric complex on LDs. ApoL6 ablation in mice decreases white adipose tissue mass and protects from diet-induced obesity; overexpression causes obesity and insulin resistance.\",\n      \"method\": \"ApoL6 knockdown and overexpression in adipocytes; LD size/TAG content measurements; Co-IP and pulldown mapping of ApoL6-Plin1 and Plin1-HSL interactions; domain truncation mapping; in vivo mouse models (KO and adipose-specific OE); lipolysis assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — multiple orthogonal methods (Co-IP, domain truncation, KO mouse, OE mouse, lipolysis assay), in vitro and in vivo validation, clear mechanistic dissection of the complex\",\n      \"pmids\": [\"38167864\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"APOL6 interacts with ACSL4 (acyl-coenzyme A synthetase long-chain family member 4) and mediates ferroptosis; APOL6 expression is regulated by STAT1, defining a STAT1/APOL6/GPX4 regulatory axis in bladder cancer cells.\",\n      \"method\": \"Co-immunoprecipitation (APOL6-ACSL4); Western blot; STAT1 inhibition/modulation experiments; ferroptosis assays in cancer cell lines\",\n      \"journal\": \"BMC cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, Co-IP for interaction, functional ferroptosis assay; mechanistic detail limited in abstract\",\n      \"pmids\": [\"39187773\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Overexpression of APOL6 in pancreatic cancer cells induces apoptosis, necroptosis, and pyroptosis with immunogenic features (immunogenic cell death), suggesting a role in activating multiple immunogenic death pathways.\",\n      \"method\": \"APOL6 overexpression plasmid transfection; flow cytometry; CCK8 assay; Western blot; qRT-PCR\",\n      \"journal\": \"Biomolecules\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, overexpression with flow cytometry readouts, limited mechanistic dissection reported in abstract\",\n      \"pmids\": [\"36979348\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"APOL6 upregulation in IFNγ-stimulated human macrophages (U937 cells) is dependent on the PI3K/AKT pathway, as PI3K/AKT inhibitor suppressed IFNγ-induced APOL6 upregulation; JAK/STAT3 and MAPK/ERK inhibitors did not suppress APOL6 upregulation under these conditions.\",\n      \"method\": \"RNA-seq; qPCR validation; pharmacological inhibition of JAK/STAT3, MAPK/ERK, and PI3K/AKT pathways in IFNγ-stimulated U937 cells\",\n      \"journal\": \"Zhongguo shi yan xue ye xue za zhi\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, pharmacological inhibitor experiment only, no direct mechanistic dissection of the pathway\",\n      \"pmids\": [\"36208271\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"A super-enhancer-derived eRNA (seRNA-1) regulates expression of Apol6 (and myoglobin) during skeletal myoblast differentiation by binding to hnRNPL via a CAAA tract; disruption of seRNA-1–hnRNPL interaction reduces Pol II and H3K36me3 deposition and Apol6/Mb transcription.\",\n      \"method\": \"eRNA knockdown in vitro and in vivo; RNA immunoprecipitation (seRNA-1/hnRNPL); ChIP for Pol II and H3K36me3; mutagenesis of CAAA tract\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (RIP, ChIP, mutagenesis, in vivo); APOL6 is a secondary target gene in this study, not the primary focus\",\n      \"pmids\": [\"31857580\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"CREB5 transcriptionally activates ApoL6 expression in neurons after spinal cord injury (SCI); ApoL6 inhibits the breakdown of neuronal lipid droplets (LDs), reducing free fatty acid release, fatty acid oxidation, ROS generation, and lipid peroxidation, thereby suppressing ferroptosis. Overexpression of ApoL6 partially reverses neuronal death and axonal growth impairment caused by CREB5 knockdown.\",\n      \"method\": \"scRNA-seq and scATAC-seq analysis; CREB5 KD/OE in primary neurons and mouse SCI model; ApoL6 OE rescue experiments; ROS, lipid peroxidation, and free fatty acid measurements; axonal growth and functional recovery assays\",\n      \"journal\": \"CNS neuroscience & therapeutics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro and in vivo experiments with KD/OE and rescue, multiple mechanistic readouts; single lab, transcriptional regulation of ApoL6 by CREB5 inferred from chromatin accessibility and rescue experiments\",\n      \"pmids\": [\"41700484\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"miR-643, transferred horizontally via exosomes from cisplatin-resistant hepatocarcinoma cells, targets APOL6 mRNA and reduces APOL6 protein levels, reversing APOL6-mediated apoptosis and conferring cisplatin resistance to recipient cells.\",\n      \"method\": \"miR-643 overexpression; drug sensitivity assays; Western blot and qPCR for APOL6; apoptosis assays; exosome transfer experiments\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, single method for each step; APOL6 as miR-643 target validated at mRNA/protein level but detailed mechanistic dissection limited\",\n      \"pmids\": [\"34071504\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"APOL6 is a BH3-only proapoptotic member of the apolipoprotein L family that induces mitochondria-mediated apoptosis via its BH3 domain (releasing cytochrome c/Smac, activating caspase-9), binds the anti-apoptotic protein Bcl-XL, blocks autophagy by promoting Beclin 1 degradation, forms ion channels causing cytolysis, and in adipocytes localizes to lipid droplets where its C-terminal domain directly binds N-terminal Perilipin1 to prevent Plin1–HSL interaction and thereby inhibit lipolysis, with ApoL6 ablation protecting mice from diet-induced obesity; additionally, APOL6 interacts with ACSL4 to mediate ferroptosis under a STAT1-regulated axis, is transcriptionally induced by IFNγ through PI3K/AKT signaling, and is transcriptionally activated by CREB5 in neurons to suppress lipid-droplet-driven ferroptosis after spinal cord injury.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"APOL6 is a BH3-only proapoptotic member of the apolipoprotein L family that couples mitochondrial cell-death control to lipid-droplet metabolism [#0, #5]. Its BH3 domain is required for mitochondria-mediated apoptosis: overexpression triggers cytochrome c and Smac/DIABLO release and caspase-9 activation, while a BH3-deletion allele is inert [#0]. APOL6 binds the anti-apoptotic protein Bcl-XL and promotes ROS-dependent, caspase-driven apoptosis; in parallel it blocks autophagy by inducing Beclin 1 degradation, p62 accumulation, and loss of LC3-II [#1]. Transient APOL6 expression is cytolytic by LDH release, though unlike other APOL family members recombinant APOL6 does not insert into planar lipid bilayers under acidic or positive-voltage conditions, distinguishing its membrane behavior from APOL1\\u2013APOL5 [#4]. In adipocytes APOL6 is a lipid-droplet-associated protein whose C-terminal domain directly binds the N-terminus of Perilipin1, preventing Plin1\\u2013HSL interaction and thereby inhibiting HSL-mediated lipolysis; APOL6, Plin1, and HSL form a trimeric complex on droplets, and APOL6 ablation reduces adipose mass and protects mice from diet-induced obesity while overexpression drives obesity and insulin resistance [#5]. APOL6 also links to ferroptosis: it interacts with ACSL4 within a STAT1/APOL6/GPX4 axis in bladder cancer [#6], and in injured neurons CREB5-driven APOL6 suppresses lipid-droplet breakdown to limit fatty-acid oxidation, lipid peroxidation, and ferroptotic death [#10]. Expression is induced by IFN\\u03b3 through PI3K/AKT signaling in macrophages [#8] and tuned post-transcriptionally and at the chromatin level by additional regulators [#9, #11].\",\n  \"teleology\": [\n    {\n      \"year\": 2005,\n      \"claim\": \"Established APOL6 as a genuine proapoptotic effector and pinned its activity to a defined structural element, answering whether the protein actively drives cell death.\",\n      \"evidence\": \"Overexpression of wild-type vs. BH3-deletion APOL6 in p53-null DLD-1 and other cancer lines with cytochrome c/Smac release and caspase-9 activation readouts\",\n      \"pmids\": [\"15671246\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No endogenous loss-of-function in physiological setting\", \"Direct binding target of the BH3 domain not identified\", \"Mechanism of caspase-8 activation unresolved\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Connected APOL6 to specific anti-apoptotic machinery and revealed a dual role suppressing autophagy, clarifying how it integrates two death/survival programs.\",\n      \"evidence\": \"Reciprocal overexpression/siRNA in lesion-derived cells; Co-IP for APOL6\\u2013Bcl-XL; ROS and caspase assays; LC3-II/p62/Beclin 1 Western and LC3 immunofluorescence\",\n      \"pmids\": [\"21646352\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of Beclin 1 degradation not defined\", \"Whether Bcl-XL binding is BH3-mediated not tested\", \"Cell-type generality unclear\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Tested whether APOL6 acts as an antiviral restriction factor, extending its functional repertoire beyond cell death.\",\n      \"evidence\": \"Transient overexpression in 293T cells with infectious HIV-1 production assay and replication-cycle follow-up\",\n      \"pmids\": [\"25980612\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single overexpression system\", \"Exact replication step not pinpointed\", \"No endogenous or knockdown validation\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Compared APOL6 membrane behavior against the rest of the family, showing its cytolytic activity is not explained by canonical bilayer insertion.\",\n      \"evidence\": \"Transient overexpression with LDH release and planar lipid bilayer electrophysiology of recombinant APOL1\\u2013APOL6 in parallel\",\n      \"pmids\": [\"34252458\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Ion conductance properties uncharacterized\", \"Mechanism of cytolysis without bilayer insertion unknown\", \"Conditions tested may not capture native insertion\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Defined a non-apoptotic, metabolic role: APOL6 directly regulates lipolysis on lipid droplets and influences whole-body adiposity, reframing it as a metabolic regulator.\",\n      \"evidence\": \"Adipocyte knockdown/overexpression, Co-IP and domain-truncation mapping of APOL6\\u2013Plin1 and Plin1\\u2013HSL, KO and adipose-specific OE mice, lipolysis and LD/TAG assays\",\n      \"pmids\": [\"38167864\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of the trimeric complex not solved\", \"Relationship between this LD function and apoptotic function unclear\", \"Regulation of APOL6 LD targeting not defined\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Linked APOL6 to ferroptosis through a physical partner and a transcriptional upstream regulator, broadening its death-pathway involvement.\",\n      \"evidence\": \"Co-IP for APOL6\\u2013ACSL4, STAT1 modulation, and ferroptosis assays in bladder cancer cells\",\n      \"pmids\": [\"39187773\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single Co-IP without reciprocal validation\", \"How APOL6 modulates GPX4 mechanistically unknown\", \"STAT1\\u2013APOL6 regulation not directly demonstrated at the promoter\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Showed that CREB5-driven APOL6 suppresses lipid-droplet-fueled ferroptosis in neurons, unifying its LD and cell-death roles in a tissue context.\",\n      \"evidence\": \"scRNA/scATAC-seq, CREB5 KD/OE and APOL6 OE rescue in primary neurons and mouse SCI model with ROS, lipid peroxidation, free fatty acid, and axonal growth readouts\",\n      \"pmids\": [\"41700484\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"CREB5 transcriptional activation inferred from accessibility/rescue, not direct promoter binding\", \"Single lab\", \"Mechanism of LD-breakdown inhibition in neurons not at molecular resolution\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How APOL6's BH3/apoptotic activity, its lipid-droplet/lipolysis function, and its ferroptosis-modulating interactions are mechanistically reconciled within one protein remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structure of APOL6 or its complexes\", \"No unified model linking membrane/cytolytic, apoptotic, and metabolic functions\", \"Endogenous physiological function in non-adipose tissues largely untested\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 1, 5]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [5]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005811\", \"supporting_discovery_ids\": [5, 10]},\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [0, 1]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [5]}\n    ],\n    \"complexes\": [\"APOL6\\u2013Plin1\\u2013HSL trimeric lipid-droplet complex\"],\n    \"partners\": [\"BCL2L1\", \"PLIN1\", \"LIPE\", \"ACSL4\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}